LCM
MRSN

Laurion Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Laurion Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,000
Closed -$865K – 1712
2017
Q3 		$865K Hold
2,000
– – ﹤0.01% 1023
2017
Q2 		$699K Buy
+2,000
New +$692K ﹤0.01% 1147

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Laurion Capital Management's MRSN Position: Q4 2017 in Review

Laurion Capital Management sold out of Mersana Therapeutics (MRSN) in Q4 2017, closing a stake of 2,000 shares — an estimated $865K sold.

Laurion Capital Management first reported a position in MRSN in Q2 2017 and held it in 2 quarters. The position peaked at $865K in Q3 2017. 50 funds tracked by Wall St. Rank hold MRSN as of Q4 2017.

  • Laurion Capital Management reported no remaining Mersana Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Laurion Capital Management sold 2,000 Mersana Therapeutics shares in Q4 2017, an estimated $865K.
  • Laurion Capital Management first reported a position in Mersana Therapeutics in Q2 2017 and held it in 2 quarters.
  • Laurion Capital Management's Mersana Therapeutics position peaked at $865K in Q3 2017.
  • 50 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.